Semaglutide significantly reduced voluntary alcohol consumption in alcohol-preferring monkeys without causing nausea or affecting water intake — the first demonstration of this effect in non-human primates.
Significant alcohol reduction, no nauseaSemaglutide reduced voluntary alcohol intake in alcohol-preferring primates compared to placebo, without emetic events or changes in water consumption — suggesting a direct effect on reward/motivation rather than sickness.
What the researchers found
In a vehicle-controlled study of 20 alcohol-preferring male vervet monkeys, semaglutide (0.05 mg/kg twice weekly subcutaneously) significantly reduced voluntary alcohol intake compared to placebo during a 4-week alcohol access period (4 hours daily, Monday through Friday).
Crucially, there were no signs of emetic events (vomiting or nausea), and water intake was not affected — two important controls suggesting that the reduction in alcohol drinking was not simply due to the monkeys feeling sick or reducing all fluid consumption. The study included a 2-week dose escalation period before alcohol was reintroduced and a 1-week washout period at the end.
Why it matters
Alcohol use disorder affects hundreds of millions of people worldwide and current treatments have limited efficacy. The observation that GLP-1 drugs might reduce alcohol consumption has generated enormous clinical interest, but the evidence has been largely from rodent studies and anecdotal human reports. Non-human primates are much closer to humans in brain structure and reward circuitry, so this primate demonstration significantly strengthens the case for clinical trials of semaglutide in alcohol use disorder.
How the study worked
This was a vehicle-controlled study in 20 male African green monkeys with demonstrated alcohol preference. After 10 days of baseline alcohol consumption measurement (4 hours daily access), monkeys were randomized to semaglutide (n=10) or vehicle (n=10), balanced for baseline alcohol intake. Semaglutide was escalated to 0.05 mg/kg over 2 weeks (without alcohol access), then maintained for 3 weeks during which alcohol consumption was measured over 20 days. A 1-week washout period followed. Alcohol intake, water intake, and emetic events were monitored.
What this study cannot tell us
The study used only male monkeys (n=10 per group), so results may not apply to females. The 4-week treatment period is short relative to the chronic nature of alcohol use disorder. The dose (0.05 mg/kg twice weekly) may not directly translate to human clinical dosing. While the monkeys preferred alcohol, they were not alcohol-dependent in the clinical sense — they didn't experience withdrawal or compulsive drinking. The study cannot determine whether semaglutide's effect would persist long-term or whether alcohol consumption would rebound after stopping treatment.
How to read the evidence
This is a well-designed, vehicle-controlled primate study with appropriate randomization and group balancing. Non-human primate studies are the closest preclinical model to human behavior. However, the small sample size (n=10 per group) and short duration limit definitive conclusions.
When this study was published
Published in 2025, this is a very recent study providing timely evidence as multiple human clinical trials investigating semaglutide for alcohol use disorder are currently underway.
The bigger picture
This study sits at the convergence of two major pharmaceutical trends: the explosive growth of GLP-1 receptor agonists and the desperate need for better alcohol addiction treatments. If semaglutide proves effective for alcohol use disorder in clinical trials, it would represent a paradigm shift — potentially treating obesity, diabetes, and addiction with a single medication. Multiple human clinical trials are now underway based on the growing preclinical and anecdotal evidence, and this primate study provides crucial translational support.
Questions still open
- Will ongoing human clinical trials confirm that semaglutide reduces alcohol consumption in people with alcohol use disorder?
- Does semaglutide reduce the rewarding properties of alcohol (wanting/liking), or does it work through a different mechanism such as satiety?
- Would the alcohol-reducing effect persist after stopping semaglutide, or would consumption return to baseline?
Common questions
Could semaglutide help people with alcohol addiction?
How might semaglutide reduce alcohol drinking?
Read the original research
Effect of the glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide on alcohol consumption in alcohol-preferring male vervet monkeys.
Psychopharmacology, 242(1), 63-70
Citation
Fink-Jensen, Anders; Wörtwein, Gitta; Klausen, Mette Kruse; Holst, Jens Juul; Hartmann, Bolette; Thomsen, Morgan; Ptito, Maurice; Beierschmitt, Amy; Palmour, Roberta M. (2025). Effect of the glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide on alcohol consumption in alcohol-preferring male vervet monkeys.. Psychopharmacology, 242(1), 63-70. https://doi.org/10.1007/s00213-024-06637-2